2022 Fiscal Year Final Research Report
Basic research on drugs that can dramatically improve the effectiveness of BNCT in multifaceted cancer control
| Project/Area Number |
21K19449
|
|---|
| Research Category |
Grant-in-Aid for Challenging Research (Exploratory)
|
| Allocation Type | Multi-year Fund |
|---|
| Review Section |
Medium-sized Section 52:General internal medicine and related fields
|
|---|
| Research Institution | Kobe University |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
澤 智裕 熊本大学, 大学院生命科学研究部(医), 教授 (30284756)
松本 孔貴 筑波大学, 医学医療系, 助教 (70510395)
沼尻 晴子 (橋井晴子) 筑波大学, 医学医療系, 講師 (00712845)
|
|---|
| Project Period (FY) |
2021-07-09 – 2023-03-31
|
| Keywords | BNCT / DDS / ナノ粒子 |
|---|
| Outline of Final Research Achievements |
The safety of SMA-glucosamine-boric acid complex (SGB) was determined to be acceptable. Cancer cell accumulation and antitumor effects on tumor cells showed that the SGB complex had a strong cytotoxic effect on tumor cells after hypoxia. When SGB complex was administered intravenously at a dose of 15 mg/kg (BA equivalent), SGB complex bound to albumin and had a plasma half-life of about 8 h in mice In SCCVII-tumor mice, the SGB complex showed remarkable antitumor effects at a dose of 10B, a few tenths of the dose of existing boron compounds (BPA).
|
| Free Research Field |
BNCT
|
| Academic Significance and Societal Importance of the Research Achievements |
新しい化合物SGBの安全性と腫瘍細胞集積性について新たな知見を得た。BNCTは加速器による治療法の開発で近年注目度の高い放射線治療である。一方、使用される薬剤についてはBPA以後、画期的なものは開発されていない。今後、新たな化合物の開発が多くおこなわれていくことが予想される。本研究はその一つとして医学の発展に寄与すると思われる。
|
